Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

779
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
779
Autoimmune Disorders01:29

Autoimmune Disorders

1.3K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.3K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

253
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
253
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

367
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
367
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

342
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
342
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

142
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
142

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factor obesity: Treatment Standard.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Trial End Points in ANCA-Associated Vasculitis: Are We Missing the Boat?

Journal of the American Society of Nephrology : JASN·2026
Same author

Development and validation of EULAR quality indicators for lupus nephritis: adherence trends and impact on clinical outcomes.

Annals of the rheumatic diseases·2026
Same author

Pivotal Clinical Trials in C3 Glomerulopathy: answers and remaining uncertainties.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Kidney failure in patients with ANCA-associated vasculitis: A systematic review of outcomes.

Autoimmunity reviews·2026
Same author

Cardiovascular disease and risk management in patients with nephrotic syndrome.

Kidney research and clinical practice·2026

Related Experiment Video

Updated: Dec 23, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.4K

Comorbidities in ANCA-associated vasculitis.

Andreas Kronbichler1, Johannes Leierer1, Philipp Gauckler1

  • 1Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.

Rheumatology (Oxford, England)
|April 30, 2020
PubMed
Summary

Patients with ANCA-associated vasculitis face high risks of blood clots and cardiovascular events. Managing these complications is crucial for improving survival rates in vasculitis patients.

Keywords:
comorbiditycoronary heart diseasedeep vein thrombosisdiabetes mellitushypercholesterolaemiahypertensionmyocardial infarctionpulmonary embolismvasculitis

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.5K
Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

136.9K

Related Experiment Videos

Last Updated: Dec 23, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.4K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.5K
Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

136.9K

Area of Science:

  • Rheumatology and Immunology
  • Cardiovascular Medicine
  • Hematology

Background:

  • While survival for ANCA-associated vasculitis (AAV) has improved, it remains suboptimal.
  • Complications from immunosuppressive treatments and comorbidities significantly impact patient outcomes.
  • Thromboembolic and cardiovascular events are major concerns in AAV management.

Purpose of the Study:

  • To review the significant risks of thromboembolic and cardiovascular events in AAV patients.
  • To highlight the link between active disease, coagulation factors, and hypercoagulable states.
  • To emphasize the need for better control of cardiovascular risk factors and tailored anticoagulation strategies.

Main Methods:

  • Review of current literature focusing on thromboembolic and cardiovascular complications in AAV.
  • Analysis of evidence linking active disease and impaired coagulation to increased thrombotic risk.
  • Examination of cardiovascular risk factors, including hypertension, diabetes, and hypercholesterolemia, in AAV patients.

Main Results:

  • A considerably increased risk of thromboembolic events is reported in AAV, associated with active disease.
  • A hypercoagulable state persists even in AAV remission, necessitating further research into anticoagulation.
  • Accelerated atherosclerosis, hypertension, diabetes, and hypercholesterolemia are common, often linked to immunosuppression or the disease itself.

Conclusions:

  • Thromboembolic and cardiovascular events pose significant threats to AAV patients' survival.
  • Current management of modifiable cardiovascular risk factors in AAV is insufficient.
  • Periodic reviews and adherence to individualized cardiovascular risk prediction guidelines are essential for AAV patient care.